These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Leukemia AND MYB, c-myb_CDS, 4602, ENSG00000118513, P10242, efg, Cmyb, c-myb AND Treatment
118 results:

  • 1. Enhancer looping protein LDB1 modulates myb expression in T-ALL cell lines in vitro by cooperating with master transcription factors.
    Li Y; Zhang Z; Yu J; Yin H; Chu X; Cao H; Tao Y; Zhang Y; Li Z; Wu S; Hu Y; Zhu F; Gao J; Wang X; Zhou B; Jiao W; Wu Y; Yang Y; Chen Y; Zhuo R; Yang Y; Zhang F; Shi L; Hu Y; Pan J; Hu S
    J Exp Clin Cancer Res; 2024 Oct; 43(1):283. PubMed ID: 39385230
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. hnRNPA0 promotes myb expression by interacting with enhancer lncRNA MY34UE-AS in human leukemia cells.
    Liu C; Wang Y; Shi M; Tao X; Man D; Zhang J; Han B
    Biochem Biophys Res Commun; 2024 Sep; 724():150221. PubMed ID: 38865811
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Transcriptome Analysis in Mexican Adults with Acute Lymphoblastic leukemia.
    Cruz-Miranda GM; Olarte-Carrillo I; Bárcenas-López DA; Martínez-Tovar A; Ramírez-Bello J; Ramos-Peñafiel CO; García-Laguna AI; Cerón-Maldonado R; May-Hau D; Jiménez-Morales S
    Int J Mol Sci; 2024 Feb; 25(3):. PubMed ID: 38339034
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Efficacy of novel agents against cellular models of familial platelet disorder with myeloid malignancy (FPD-MM).
    Mill CP; Fiskus WC; DiNardo CD; Reville P; Davis JA; Birdwell CE; Das K; Hou H; Takahashi K; Flores L; Ruan X; Su X; Loghavi S; Khoury JD; Bhalla KN
    Blood Cancer J; 2024 Feb; 14(1):25. PubMed ID: 38316746
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Suppression of super-enhancer-driven TAL1 expression by KLF4 in T-cell acute lymphoblastic leukemia.
    Noura M; Matsuo H; Yasuda T; Tsuzuki S; Kiyoi H; Hayakawa F
    Oncogene; 2024 Feb; 43(6):447-456. PubMed ID: 38102337
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Preclinical efficacy of targeting epigenetic mechanisms in AML with 3q26 lesions and EVI1 overexpression.
    Birdwell CE; Fiskus W; Kadia TM; Mill CP; Sasaki K; Daver N; DiNardo CD; Pemmaraju N; Borthakur G; Davis JA; Das K; Sharma S; Horrigan S; Ruan X; Su X; Khoury JD; Kantarjian H; Bhalla KN
    Leukemia; 2024 Mar; 38(3):545-556. PubMed ID: 38086946
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Therapeutic targeting of EP300/CBP by bromodomain inhibition in hematologic malignancies.
    Nicosia L; Spencer GJ; Brooks N; Amaral FMR; Basma NJ; Chadwick JA; Revell B; Wingelhofer B; Maiques-Diaz A; Sinclair O; Camera F; Ciceri F; Wiseman DH; Pegg N; West W; Knurowski T; Frese K; Clegg K; Campbell VL; Cavet J; Copland M; Searle E; Somervaille TCP
    Cancer Cell; 2023 Dec; 41(12):2136-2153.e13. PubMed ID: 37995682
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Analysis of single-cell sequencing results of an elderly patient with myeloid leukemia reveals high expression of multiple oncogenes in monocytes and hematopoietic stem cells.
    Xu X; Xiong M; Ye H; Qi Y; Zhao Y
    Hematology; 2023 Dec; 28(1):2240129. PubMed ID: 37535066
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. A phase I study of the combination of palbociclib and dexamethasone for the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia.
    Wilde L; Porazzi P; Trotta R; De Dominici M; Palmisiano N; Keiffer G; Rancani K; Yingling K; Calabretta B; Kasner M
    Leuk Res; 2023 Jun; 129():107075. PubMed ID: 37079999
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Harnessing the myb-dependent TAL1 5'super-enhancer for targeted therapy in T-ALL.
    Smith C; Touzart A; Simonin M; Tran-Quang C; Hypolite G; Latiri M; Andrieu GP; Balducci E; Dourthe MÉ; Goyal A; Huguet F; Petit A; Ifrah N; Baruchel A; Dombret H; Macintyre E; Plass C; Ghysdael J; Boissel N; Asnafi V
    Mol Cancer; 2023 Jan; 22(1):12. PubMed ID: 36650499
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Combined Approach to Leukemic Differentiation Using Transcription Factor PU.1-Enhancing Agents.
    Bašová P; Paszeková H; Minařík L; Dluhošová M; Burda P; Stopka T
    Int J Mol Sci; 2022 Jun; 23(12):. PubMed ID: 35743167
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Prognostic utility of key copy number alterations in T cell acute lymphoblastic leukemia.
    Kumari S; Ali MS; Singh J; Arora M; Verma D; Pandey AK; Benjamin M; Bakhshi S; Palanichamy JK; Sharma A; Singh I; Tanwar P; Singh AR; Pushpam D; Qamar I; Chopra A
    Hematol Oncol; 2022 Oct; 40(4):577-587. PubMed ID: 35644022
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Src-Family Protein Kinase Inhibitors Suppress myb Activity in a p300-Dependent Manner.
    Biyanee A; Yusenko MV; Klempnauer KH
    Cells; 2022 Mar; 11(7):. PubMed ID: 35406726
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Effective therapy for AML with RUNX1 mutation by cotreatment with inhibitors of protein translation and BCL2.
    Mill CP; Fiskus W; DiNardo CD; Birdwell C; Davis JA; Kadia TM; Takahashi K; Short N; Daver N; Ohanian M; Borthakur G; Kornblau SM; Green MR; Qi Y; Su X; Khoury JD; Bhalla KN
    Blood; 2022 Feb; 139(6):907-921. PubMed ID: 34601571
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Identification of mutations that cooperate with defects in B cell transcription factors to initiate leukemia.
    Heltemes-Harris LM; Hubbard GK; LaRue RS; Munro SA; Yang R; Henzler CM; Starr TK; Sarver AL; Kornblau SM; Farrar MA
    Oncogene; 2021 Oct; 40(43):6166-6179. PubMed ID: 34535769
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Hsa-circ_0003420 induces apoptosis in acute myeloid leukemia stem cells and impairs stem cell properties.
    Lin G; Fei Y; Zhang Y
    Immunopharmacol Immunotoxicol; 2021 Oct; 43(5):622-631. PubMed ID: 34477035
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Constitutive JAK/STAT signaling is the primary mechanism of resistance to JAKi in TYK2-rearranged acute lymphoblastic leukemia.
    Tavakoli Shirazi P; Eadie LN; Page EC; Heatley SL; Bruning JB; White DL
    Cancer Lett; 2021 Aug; 512():28-37. PubMed ID: 33971281
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. C/EBPβ is a myb- and p300-cooperating pro-leukemogenic factor and promising drug target in acute myeloid leukemia.
    Yusenko MV; Trentmann A; Casolari DA; Abdel Ghani L; Lenz M; Horn M; Dörner W; Klempnauer S; Mootz HD; Arteaga MF; Mikesch JH; D'Andrea RJ; Gonda TJ; Müller-Tidow C; Schmidt TJ; Klempnauer KH
    Oncogene; 2021 Jul; 40(29):4746-4758. PubMed ID: 33958723
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. [Effect of MiR-96 on Cell Invasion and Apoptosis in Pediatric Acute Myeloid leukemia via Regulating myb].
    Wang XL; Wang WF; Hao JM
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Apr; 29(2):439-444. PubMed ID: 33812412
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Inhibiting the "Undruggable" RAS/Farnesyltransferase (FTase) Cancer Target by Manumycin-related Natural Products.
    Silva LR; da Silva-Júnior EF
    Curr Med Chem; 2022; 29(2):189-211. PubMed ID: 33719954
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 6.